Importation Rules - Mpje

1. Identify the correct DSCSA response: A package appears tampered and lot numbers do not match paperwork.

   Quarantine as suspect product and begin investigation/verification steps. DSCSA mandates treating tampered or mismatched products as suspect, requiring isolation and verification to prevent potential harm.

2. What DSCSA category includes a dispenser that distributes to another dispenser without a patient-specific Rx?

   It may be acting as a wholesale distributor (not a dispenser-only activity). Distributing without patient-specific prescriptions exceeds dispenser scope, triggering wholesale distributor regulations under DSCSA for chain security.

3. Identify the DSCSA rule for receiving transaction data when a dispenser buys from a wholesaler.

   Dispenser must receive TI/TH/TS for the transaction. DSCSA requires dispensers to obtain these documents for traceability, verifying product legitimacy and supply chain compliance.

4. Identify the correct action: A dispenser receives product from a supplier not licensed in the state.

   Do not accept; purchase only from an authorized (properly licensed) trading partner. DSCSA prohibits acceptance from unauthorized suppliers to protect against introduction of counterfeit or diverted drugs into the chain.

5. Which option best describes when a pharmacy becomes a "wholesale distributor" under federal concepts?

   When it distributes prescription drugs beyond dispensing to its own patients. Federal law classifies such distribution as wholesale activity, requiring appropriate licensure to ensure regulatory oversight and compliance.

6. What is the general rule under the FDCA for importing drugs into the United States?

   Importation is prohibited unless the drug meets FDCA requirements. The FDCA prohibits importation of drugs that fail to comply with U.S. standards for safety, efficacy, and labeling to protect public health.

7. Identify the recordkeeping rule: A dispenser discards transaction records after 3 years to save space.

   Noncompliant; DSCSA requires retention for 6 years. DSCSA's 6-year retention requirement ensures records are available for regulatory enforcement, making shorter periods noncompliant.

8. What is the DSCSA definition of an illegitimate product?

   Product credible evidence shows is counterfeit, diverted, or otherwise unlawful. DSCSA classifies products as illegitimate upon evidence of risks, mandating quarantine and notifications to prevent distribution of harmful drugs.

9. Identify the three DSCSA transaction documents that typically accompany a product transfer.

   Transaction Information, Transaction History, Transaction Statement (TI/TH/TS). These DSCSA documents provide detailed transaction data, history, and compliance statements to enable product tracing and verification.

10. Choose the compliant practice: A pharmacy transfers stock to another pharmacy without patient prescriptions.

    Only if permitted and performed under wholesale distribution rules and licensure. Transfers without prescriptions constitute wholesale distribution, necessitating compliance with DSCSA licensure and transaction rules.

11. Which federal act governs wholesale prescription drug distribution standards and licensing baselines?

    Prescription Drug Marketing Act (PDMA). PDMA sets standards for wholesale distribution, including licensing and recordkeeping, to prevent drug diversion and ensure supply chain integrity.

12. Which DSCSA requirement applies before a dispenser accepts ownership of a prescription drug product?

    Verify the trading partner is authorized (licensed/registered as required). DSCSA requires verification of trading partner authorization to prevent transactions with unlicensed entities and reduce counterfeit risks.

13. What is the general federal rule for distributing prescription drug samples to pharmacies?

    Pharmacies generally may not receive or distribute prescription drug samples. PDMA restricts sample distribution to licensed practitioners or hospital pharmacies to prevent misuse and diversion in retail settings.

14. Find the compliance outcome: A pharmacy imports a foreign-labeled Rx drug for routine dispensing.

    Noncompliant; routine importation for dispensing is generally prohibited. FDCA bans routine importation of unapproved foreign drugs to ensure compliance with U.S. safety, efficacy, and labeling requirements.

15. What federal law establishes supply chain tracing, product identifiers, and verification duties?

    Drug Supply Chain Security Act (DSCSA). DSCSA mandates traceability through documentation and identifiers to secure the pharmaceutical supply chain against counterfeits and diversions.

16. What is the DSCSA minimum record retention period for transaction documentation?

    6 years. DSCSA mandates 6-year retention to support audits, recalls, and investigations ensuring long-term supply chain accountability.

17. Which DSCSA feature is used to verify a product package during investigations (serialization)?

    Product identifier (standardized numerical identifier on the package). DSCSA's product identifier, including serialization, allows unique package verification to detect counterfeits during supply chain investigations.

18. What is the federal rule on pharmacies purchasing prescription drugs from unlicensed sources?

    Prohibited; pharmacies must buy only from authorized trading partners. DSCSA mandates purchases from authorized partners to maintain a secure, closed supply chain free from illegitimate products.

19. What is the PDMA rule on selling, purchasing, or trading prescription drug samples?

    It is prohibited. PDMA bans commercial transactions of samples to ensure they serve promotional purposes for practitioners, not resale or profit.

20. What is the DSCSA term for a pharmacy that dispenses prescription drugs to a patient?

    Dispenser. DSCSA classifies dispensers as entities providing prescription drugs directly to patients, subject to specific transaction and verification requirements.

21. What is the DSCSA definition of a suspect product?

    Product potentially counterfeit, diverted, stolen, or otherwise illegitimate. DSCSA identifies suspect products based on indicators of potential risks, requiring quarantine and investigation to safeguard the supply chain.

22. What is the key legal barrier to routine reimportation of U.S.-made prescription drugs?

    Reimportation is generally prohibited except under narrow statutory exceptions. FDCA bans reimportation to prevent risks of adulteration, counterfeiting, or mishandling during foreign distribution and storage.

23. What is the DSCSA term for an entity that sells prescription drugs to a dispenser or other entity?

    Wholesale distributor. DSCSA defines wholesale distributors as entities distributing prescription drugs to other trading partners, requiring licensure and compliance duties.

24. Identify the FDA program that allows limited importation of foreign-approved drugs during shortages.

    FDA drug shortage importation enforcement discretion (temporary). FDA temporarily exercises enforcement discretion to allow importation of foreign drugs addressing critical U.S. shortages without domestic alternatives.

25. What is the DSCSA action when a dispenser determines a product is illegitimate?

    Quarantine and notify FDA and trading partners as required. DSCSA protocols require isolating illegitimate products and alerting authorities to mitigate health risks and facilitate corrective actions.

Study these flashcards